GRAIL INC (GRAL) Stock Price, Quote, News and Overview
NASDAQ:GRAL - Nasdaq - US3847471014 - Common Stock - Currency: USD
GRAL Quote, Performance and Key Statistics
32.96
-0.12 (-0.36%)
The current stock price of GRAL is 32.96 USD. In the past month the price decreased by -24.04%. In the past year, price increased by 103.96%.
GRAL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.78 | 351.27B | ||
| AMGN | AMGEN INC | 13.05 | 153.09B | ||
| GILD | GILEAD SCIENCES INC | 14.25 | 137.18B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.17 | 96.46B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.27 | 60.44B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 56.73B | ||
| ARGX | ARGENX SE - ADR | 72.53 | 41.15B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.66 | 32.28B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.77B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.85B | ||
| INSM | INSMED INC | N/A | 20.74B | ||
| NTRA | NATERA INC | N/A | 19.26B |
Related stock screener links
About GRAL
Company Profile
GRAIL, Inc. is a healthcare company. The company is headquartered in Menlo Park, California and currently employs 1,000 full-time employees. The company went IPO on 2024-06-12. The firm is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
Company Info
GRAIL INC
1525 O'brien Drive
Menlo Park CALIFORNIA US
Employees: 1000
Phone: 18336942553
GRAIL INC / GRAL FAQ
What is the stock price of GRAIL INC today?
The current stock price of GRAL is 32.96 USD. The price decreased by -0.36% in the last trading session.
What is the ticker symbol for GRAIL INC stock?
The exchange symbol of GRAIL INC is GRAL and it is listed on the Nasdaq exchange.
On which exchange is GRAL stock listed?
GRAL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for GRAIL INC stock?
10 analysts have analysed GRAL and the average price target is 41.31 USD. This implies a price increase of 25.33% is expected in the next year compared to the current price of 32.96. Check the GRAIL INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GRAIL INC worth?
GRAIL INC (GRAL) has a market capitalization of 1.19B USD. This makes GRAL a Small Cap stock.
How many employees does GRAIL INC have?
GRAIL INC (GRAL) currently has 1000 employees.
What are the support and resistance levels for GRAIL INC (GRAL) stock?
GRAIL INC (GRAL) has a support level at 32.89 and a resistance level at 46.3. Check the full technical report for a detailed analysis of GRAL support and resistance levels.
Is GRAIL INC (GRAL) expected to grow?
The Revenue of GRAIL INC (GRAL) is expected to grow by 18.26% in the next year. Check the estimates tab for more information on the GRAL EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy GRAIL INC (GRAL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GRAL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GRAL, evaluating the profitability, health, valuation and growth aspects
- GRAIL INC (GRAL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GRAIL INC (GRAL) Sales and EPS estimates to see what analysts future expectations are.
- GRAIL INC (GRAL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GRAIL INC (GRAL) Insider and Institutional Ownership to learn about the owners and their transactions.
- GRAIL INC (GRAL) Stock Chart to make your own analysis
- GRAIL INC (GRAL) Latest news and press-releases to stay up to date.
Does GRAIL INC (GRAL) stock pay dividends?
GRAL does not pay a dividend.
When does GRAIL INC (GRAL) report earnings?
GRAIL INC (GRAL) will report earnings on 2025-08-12.
What is the Price/Earnings (PE) ratio of GRAIL INC (GRAL)?
GRAIL INC (GRAL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-60.98).
What is the Short Interest ratio of GRAIL INC (GRAL) stock?
The outstanding short interest for GRAIL INC (GRAL) is 17.83% of its float. Check the ownership tab for more information on the GRAL short interest.
GRAL Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to GRAL. When comparing the yearly performance of all stocks, GRAL is one of the better performing stocks in the market, outperforming 91.67% of all stocks.
GRAL Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to GRAL. GRAL has a great financial health rating, but its profitability evaluates not so good.
GRAL Financial Highlights
Over the last trailing twelve months GRAL reported a non-GAAP Earnings per Share(EPS) of -60.98. The EPS decreased by -15.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -67.23% | ||
| ROE | -79.31% | ||
| Debt/Equity | 0 |
GRAL Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 76% to GRAL. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 79.08% and a revenue growth 18.26% for GRAL